Heart Test Laboratories, d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, announced that an independent study utilizing its MyoVista proprietary technology was featured in Advocate Aurora Health’s Journal of Patient-Centered Research and Reviews, an open access, peer-reviewed medical journal devoted to advancing patient centered care practices, health outcomes, and patient experiences. The publication concluded that the MyoVista technology ECG-derived machine learning model “provides a cost-effective strategy for predicting patient subgroups in whom an integrated milieu of systolic and diastolic dysfunction is associated with a high-risk of major adverse cardiovascular events (MACE).” “This independent study demonstrates the opportunity that AI-ECG algorithms could bring to improving health outcomes. I believe the solution to unnecessary cardiac deaths will come from low-cost, front-line screening using AI-ECGs. Imagine the day where you can go to your primary care physician and a simple 20-second ECG test shows not only whether you have early-stage heart disease, but also whether you are at high-risk of a major adverse cardiovascular event in the next three years,” stated Andrew Simpson, CEO of HeartSciences.
